<h1 id="post-exposure-prophylaxis-pep-non-occupational-contact">Post-Exposure Prophylaxis (PEP): Non-Occupational Contact</h1>
<p><strong>National Clinicians’ Post-Exposure Prophylaxis Hotline of the National HIV/AIDS Clinicians’ Consultation Center</strong></p>
<ul>
<li><strong>Phone:</strong> <a href="tel:8884484911%20">1-888-448-4911</a> (24 hrs/day)</li>
<li>To consult on occupational AND non-occupational exposure to HIV</li>
</ul>
<h2 id="baseline-testing-of-exposed-patient">Baseline Testing of Exposed Patient</h2>
<ul>
<li>HIV</li>
<li>Hepatitis B (specifically HBsAb for immunity) </li>
<li>Hepatitis C antibody </li>
<li>Gonorrhea</li>
<li>Chlamydia </li>
<li>Syphilis</li>
<li>CBC</li>
<li>Creatinine</li>
<li>LFT</li>
<li>Pregnancy, if appropriate </li>
</ul>
<h2 id="risk-of-hiv">Risk of HIV</h2>
<ul>
<li>Receptive anal intercourse: 1-30% risk</li>
<li>Insertive anal or receptive vaginal intercourse: 0.1-10% risk</li>
<li>Oral intercourse: “very low risk” but not zero risk</li>
<li>Needle sharing with injection drug use: 0.67% per needle-sharing contact </li>
</ul>
<h2 id="high-risk-source-patient">High-Risk Source Patient</h2>
<ul>
<li>Known HIV+ source patient </li>
<li>High-risk populations</li>
<li>Men who have sex with men+/-women</li>
<li>Commercial sex workers</li>
<li>Injection drug users</li>
<li>History of incarceration</li>
<li>From a country with HIV seroprevalence ≥ 1%</li>
<li>Persons with sexual partner in this high-risk population group </li>
</ul>
<h2 id="if-decide-to-give-pep-for-possible-hiv-exposure">If Decide to Give PEP for Possible HIV Exposure</h2>
<ul>
<li><strong>Timing:</strong> The sooner the treatment, the better. Starting treatment ≤ 48 hours after exposure is best. Still eligible if present ≤ 72 hours per CDC.</li>
<li><strong>Effectiveness:</strong> PEP is associated with 81% decrease in HIV transmission.</li>
<li><strong>Duration of treatment</strong> = 28 days</li>
</ul>
<p><strong>TREATMENT OPTIONS:</strong></p>
<p>Option #1: <strong>Combivir</strong> (300 mg <span class="drug">zidovudine</span>-150 mg <span class="drug">lamivudine</span>)- 1 tab po BID</p>
<ul>
<li>Side Effects:</li>
<li>Nausea</li>
<li>Anemia</li>
<li>Hepatotoxic</li>
<li>Neutropenia</li>
<li>Asthenia</li>
</ul>
<p>Option #2: <strong>Truvada</strong> (300 mg <span class="drug">tenofovir</span>-200 mg <span class="drug">emtricitabine</span>) – 1 tab po Qday (Side effects: Nephrotoxic)
For very high-risk exposure: Can add to Option #1 or #2:</p>
<ul>
<li><strong>Kaletra (<span class="drug">ritonavir</span>-<span class="drug">lopinavir</span>)</strong> (Side effects: Hepatotoxic, diarrhea), or</li>
<li><p><strong><span class="drug">Ritonavir</span></strong> plus <strong><span class="drug">Atazanavir</span></strong> </p>
<ul>
<li>Side Effects:</li>
<li>Hepatotoxic</li>
<li>jaundice</li>
<li>renal stones</li>
</ul>
</li>
<li><p><strong><span class="drug">Ritonavir</span></strong> plus <strong><span class="drug">Darunavir</span></strong> (Side effects: Hepatotoxic, diarrhea)</p>
</li>
</ul>
<p><strong>Followup HIV and syphilis test at 4-6 weeks, 3 months, 6 months post-exposure</strong></p>
<h2 id="additional-treatment">Additional Treatment</h2>
<p><a href="http://www.cdc.gov/std/treatment/2010/sexual-assault.htm">CDC Sexual Assault and STD website</a></p>
<ul>
<li><strong><span class="drug">Ceftriaxone</span></strong> 250 mg IM x 1 (for Gonorrhea) - or can give IV</li>
<li><strong><span class="drug">Azithromycin</span></strong> 1 g po x 1 (for Chlamydia)</li>
<li><strong><span class="drug">Metronidazole</span></strong> 2 g po x 1 (for trichomonas)</li>
<li>Consider <strong>emergency contraception</strong> for women</li>
<li><strong>Hep B vaccination</strong>, if not fully vaccinated – need to finish series at 1-2 &amp; 4-6 mo </li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19864675">Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29;361(18):1768-75.</a></li>
</ul>
